Article: Ekso’s Q4 pre-announcement ‘bodes well’ for 2020 growth, says H.C. Wainwright

Article - Media

Ekso’s Q4 pre-announcement ‘bodes well’ for 2020 growth, says H.C. Wainwright

TheFly, 10 January 2020

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $1.20 price target on Ekso Bionics, saying the pre-announced “record” fourth quarter “bodes well” for continued growth in 2020.

Read full article.

 

Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.

 

RELATED:

Article: Ekso Bionics Announces Closing of $5.0 Million Registered Direct Offering

Article - Media

Ekso Bionics Announces Closing of $5.0 Million Registered Direct Offering

GlobeNewswire, 20 December 2019

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the closing of its previously announced registered direct offering of 11,111,116 shares of its common stock and warrants to purchase up to 8,333,337 shares of its common stock, at a combined purchase price of $0.45 per share and associated warrant, for aggregate gross proceeds of approximately $5.0 million.

Read full article.

 

Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.
RELATED:

Article: H.C. WAINWRIGHT STICKS TO ITS BUY RATING FOR EKSO BIONICS (EKSO)

Article - Media

H.C. WAINWRIGHT STICKS TO ITS BUY RATING FOR EKSO BIONICS (EKSO)

Catie Powers

Markets.co, 31 October 2019

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a rating on EKSO BIONICS ( – Research Report) today and set a price target of $1.20. The company’s shares closed last Monday at $0.66, close to its 52-week low of $0.48.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.
RELATED:

Article: H.C. Wainwright Starts Ekso Bionics (EKSO) at Buy

Article - Media

H.C. Wainwright Starts Ekso Bionics (EKSO) at Buy

StreetInsider.com, 28 October 2019

H.C. Wainwright analyst Swayampakula Ramakanth initiates coverage on Ekso Bionics (NASDAQ: EKSO) with a Buy rating and a price target of $1.20.

Read full article.

 

Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.

RELATED:

Article: H.C. Wainwright & Co. Is Once Again Ranked #1 by PlacementTracker

Article - Media

H.C. Wainwright & Co. Is Once Again Ranked #1 by PlacementTracker

BusinessWire, 22 October 2019

H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume during the third quarter of 2019, maintaining the Firm’s top position for 18 consecutive quarters, in PlacementTracker’s Market League Tables.

In addition to being the #1 Investment Bank for CMPO, RD and PIPE transactions, H.C. Wainwright executed 150 transactions in the first three quarters of 2019 totaling $5.5 Billion in transaction value. The H.C. Wainwright team has been the #1 ranked underwriter/placement agent by deal volume cumulatively since 1998.

Read full article.

 

Comment: This company is alleged to be one of the top front-runners helping naked short sellers destroy promising companies.

Learn more: HCWainwright @ NSS

Article: H.C. Wainwright Initiates Coverage On Ekso Bionics Holdings with Buy Rating, Announces $1.2 Price Target

Article - Media

H.C. Wainwright Initiates Coverage On Ekso Bionics Holdings with Buy Rating, Announces $1.2 Price Target

Benzinga, 1 October 2019

Read full article.

 

Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.

RELATED:

THE DOLLAR HAS NO INTRINSIC VALUE : DO YOUR ASSETS?